Proliferation markers for the differential diagnosis of tumor and inflammation

Current Pharmaceutical Design

Volumn 14, Issue 31, 2008, Pages 3326-3339

  van Waarde, Aren ^a   Elsinga, Philip H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINO 3 FLUOROCYCLOBUTANE 1 CARBOXYLIC ACID F 18; 2 AMINO 2 METHYLPROPIONIC ACID C 11; 2 FLUOROTYROSINE F 18; 2 IODOTYROSINE I 123; 3 FLUORO ALPHA METHYLTYROSINE F 18; 3' FLUOROTHYMIDINE F 18; 4 IODOPHENYLALANINE I 123; ALPHA N 1 ACETYLAMINOISOBUTYRIC ACID C 11; CHOLINE C 11; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLCHOLINE F 18; FLUOROMETHYLETHYLCHOLINE F 18; FLUOROPROPYLCHOLINE F 18; FLUOROURACIL; LEUCINE I 11; METHIONINE C 11; METHYLMETHIONINE C 11; METHYLTHYMIDINE C 11; O 2 FLUOROETHYLTYROSINE F 18; O METHYLTYROSINE C 11; RADIOPHARMACEUTICAL AGENT; THYMIDINE KINASE; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; TUMOR MARKER;

AMINO ACID TRANSPORT; B LYMPHOCYTE; BACTERIAL INFECTION; BLOOD BRAIN BARRIER; BRAIN ABSCESS; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DRUG ELIMINATION; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVITY; FALSE POSITIVE RESULT; HUMAN; IMAGE ANALYSIS; INFLAMMATION; ISOTOPE LABELING; LYMPHOCYTE PROLIFERATION; NONHUMAN; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STRUCTURE ANALYSIS; TREATMENT PLANNING; TUMOR; ANIMAL; CELL PROLIFERATION; NEOPLASM; PATHOLOGY; SCINTISCANNING;

ANIMALS; CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFLAMMATION; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 59649124608     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786549399     Document Type: Review

References (211)

1. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-Dglucose (F-18): Nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670-5.
2. Herholz K, Rudolf J, Heiss WD. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurooncol 1992; 12: 159-65.
3. Kubota K. From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001; 15: 471-86
4. Scharko AM, Perlman SB, Hinds PW, Hanson JM, Uno H, Pauza CD. Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques. Proc Natl Acad Sci U S A 1996; 93: 6425-30.
5. Wallace M, Pyzalski R, Horejsh D, Brown C, Djavani M, Lu Y, et al. Whole body positron emission tomography imaging of activated lymphoid tissues during acute simian-human immunodeficiency virus 89.6PD infection in rhesus macaques. Virology 2000; 274: 255-61.
6. Jones HA, Clark RJ, Rhodes CG, Schofield JB, Krausz T, Haslett C. In vivo measurement of neutrophil activity in experimental lung inflammation. Am J Respir Crit Care Med 1994; 149: 1635-9.
7. 18F-FDG uptake in experimental soft-tissue abscesses in rats. Radiology 2002; 223: 446-51.
8. 18F] fluoro-D-glucose by fungal-associated inflammation: The standardized uptake value is greater for lesions of blastomycosis than for lymphoma in dogs with naturally occurring disease. Mol Imaging Biol 2002; 4: 201-7.
9. Bassett CL, Daniel GB, Bochsler PN, Legendre AM, Smith GT. Characterization of uptake of 2-deoxy-2-[18F]fluoro-D-glucose by fungal-associated inflammation: The differential uptake ratio for blastomyces-associated lesions is as high as for lymphoma and higher than for turpentine abscesses in experimentally induced lesions in rats. Mol Imaging Biol 2002; 4: 193-200.
10. Brudin LH, Valind SO, Rhodes CG, Pantin CF, Sweatman M, Jones T, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994; 21: 297-305.
11. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-9.
12. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995; 36: 1301-6.
13. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK. Brown adipose tissue: A factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging 2002; 29: 1393-8.
14. 18F-FDG uptake in adipose tissue and muscle: A potential source of false-positives for PET. J Nucl Med 2003; 44: 1789-96.
15. 18F-FDG PET/CT. J Nucl Med 2003; 44: 1267-70.
16. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiographics 1999; 19: 61-77.
17. 18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003; 30: 682-8.
18. Ishii K, Hosono MN, Wada Y, Maeda M, Kondo S, Takada Y, et al. Usefulness of FDG-microPET for early evaluation of therapeutic effects on VX2 rabbit carcinoma. Ann Nucl Med 2006; 20: 123-30.
19. 18F-FDG uptake in tumor lesions after chemotherapy. J Nucl Med 2007; 48: 390-7.
20. Zhao S, Kuge Y, Tsukamoto E, Mochizuki T, Kato T, Hikosaka K, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med 2001; 28: 730-5.
21. Zhao S, Kuge Y, Kohanawa M, Takahashi T, Kawashima H, Temma T, et al. Extensive FDG uptake and its modification with corticosteroid in a granuloma rat model: An experimental study for differentiating granuloma from tumors. Eur J Nucl Med Mol Imaging 2007; 34: 2096-2105.
22. Bustos R, Sobrino F. Stimulation of glycolysis as an activation signal in rat peritoneal macrophages. Effect of glucocorticoids on this process. Biochem J 1992; 282: 299-303.
23. Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, Wu H, Burger C, Bernd L, et al. The role of quantitative 18F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002; 43: 510-8.
24. Gupta N, Gill H, Graeber G, Bishop H, Hurst J, Stephens T. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest 1998; 114: 1105-11.
25. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 1994; 35: 104-12.
26. 18F-FDG PET after radiofrequency ablation: Is timing everything? J Nucl Med 2006; 47: 1235-7.
27. 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun 2005; 26: 315-21.
28. Hamada K, Tomita Y, Ueda T, Enomoto K, Kakunaga S, Myoui A, et al. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors. Ann Nucl Med 2006; 20: 671-5.
29. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26: 22-30.
30. 18F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000; 89: 2547-54.
31. 18F]FDG uptake in nude mice with tumors and inflammation: Correlated with histopathology and micro-autoradiography. Kaohsiung J Med Sci 2005; 21: 258-66.
32. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N, et al. FDG PET of primary benign and malignant bone tumors: Standardized uptake value in 52 lesions. Radiology 2001; 219: 774-7.
33. Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006; 82: 1016-20.
34. Hubner KF, Buonocore E, Gould HR, Thie J, Smith GT, Stephens S, et al. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. Clin Nucl Med 1996; 21: 941-9.
35. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, et al. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188: 487-90.
36. Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34: 567-75.
37. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26: 1345-8.
38. 18F-FDG PET. J Nucl Med 2005; 46: 1819-24.
39. 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2005; 32: 389-97.
40. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42: 1412-7.
41. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003; 44: 540-8.
42. Hamazawa Y, Koyama K, Okamura T, Wada Y, Wakasa T, Okuma T, et al. Comparison of dynamic FDG-microPET study in a rabbit turpentine-induced inflammatory model and in a rabbit VX2 tumor model. Ann Nucl Med 2007; 21: 47-55.
43. 8F]fluoro-2′-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl Med Commun 2004; 25: 819-23.
44. Kok PJ, van Eerd JE, Boerman OC, Corstens FH, Oyen WJ. Biodistribution and imaging of FDG in rats with LS174T carcinoma xenografts and focal Escherichia coli infection. Cancer Biother Radiopharm 2005; 20: 310-5.
45. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34: 414-9
46. van Waarde A, Been LB, Ishiwata K, Dierckx RA, Elsinga PH. Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: An in vitro study in glioma cells. J Nucl Med 2006; 47: 1538-45.
47. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005; 65: 9369-76.
48. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: Enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002; 62: 1966-70.
49. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Suda Y, Sekine T, et al. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res 1999; 90: 419-24.
50. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez- Pineiro L, Sanchez J, Bonilla F, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002; 296: 580-3.
51. Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, et al. Increased choline kinase activity in human breast carcinomas: Clinical evidence for a potential novel antitumor strategy. Oncogene 2002; 21: 4317-22.
52. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004; 64: 6732-9.
53. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999; 59: 80-4.
54. Katz-Brull R, Margalit R, Degani H. Differential routing of choline in implanted breast cancer and normal organs. Magn Reson Med 2001; 46: 31-8.
55. 13C-nuclear magnetic resonance (NMR) spectroscopy study. Cancer Res 1995; 55: 5140-5.
56. 31P NMR spectroscopy. J Biol Chem 1987; 262: 14875-8.
57. Al Saeedi F, Smith T, Welch A. [Methyl-3H]-choline incorporation into MCF-7 cells: Correlation with proliferation, choline kinase and phospholipase D assay. Anticancer Res 2007; 27: 901-6.
58. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez dM, V, Cejas P, et al. Expression of choline kinase alpha to predict outcome in patients with early-stage nonsmall-cell lung cancer: A retrospective study. Lancet Oncol 2007; 8: 889-97.
59. Rodriguez-Gonzalez A, de Molina RA, Banez-Coronel M, Megias D, Lacal JC. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int J Oncol 2005; 26: 999-1008.
60. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene 2004; 23: 8247-59.
61. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Ramos MA, del Carmen Nunez M, Campos J, et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003; 22: 8803-12.
62. Rodriguez-Gonzalez A, Ramirez de Molina A, itez-Rajal J, Lacal JC. Phospholipase D and choline kinase: Their role in cancer development and their potential as drug targets. Prog Cell Cycle Res 2003; 5: 191-201
63. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: A target in cancer cells? J Cell Biochem 2003; 90: 525-33.
64. Yoshimoto M, Waki A, Obata A, Furukawa T, Yonekura Y, Fujibayashi Y. Radiolabeled choline as a proliferation marker: Comparison with radiolabeled acetate. Nucl Med Biol 2004; 31: 859-65.
65. 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42: 1805-14.
66. 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 2001; 61: 110-7.
67. 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002; 43: 187-99.
68. 18F-labeled choline analogs. J Nucl Med 2007; 48: 1225.
69. 18F-FDG PET. Ann Nucl Med 2004; 18: 409-17.
70. Yanagawa T, Watanabe H, Inoue T, Ahmed AR, Tomiyoshi K, Shinozaki T, et al. Carbon-11 choline positron emission tomography in musculoskeletal tumors: Comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. J Comput Assist Tomogr 2003; 27: 175-82.
71. 18F-FDG PET. J Nucl Med 2003; 44: 1051-6.
72. 11C-choline PET: First clinical experience. Eur J Nucl Med Mol Imaging 2002; 29: 1283-8.
73. 11Ccholine PET. J Nucl Med 2003; 44: 331-5.
74. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39: 990-5.
75. 4-administration. Nucl Med Biol 2004; 31: 269-75.
76. 18F-fluoromethylcholine and 2-deoxy-D-glucose in the distribution of tumor and inflammation. Ann Nucl Med 2006; 20: 527-33.
77. Shinoura N, Nishijima M, Hara T, Haisa T, Yamamoto H, Fujii K, et al. Brain tumors: Detection with C-11 choline PET. Radiology 1997; 202: 497-503.
78. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET. Nucl Med Commun 2003; 24: 273-9.
79. 18F-FDG in acute cerebral radiation injury in the rat: Implications for separation of radiation necrosis from tumor recurrence. J Nucl Med 2004; 45: 1931-8.
80. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004; 31: 312-6.
81. Matter CM, Wyss MT, Meier P, Spath N, von LT, Lohmann C, et al. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler Thromb Vasc Biol 2006; 26: 584-9.
82. van Waarde A., Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med 2006; 47: 150-4.
83. 18F-FDG PET imaging in brain tumours. Nucl Med Commun 2008; 29: 354-8.
84. 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 2004; 31: 1064-72.
85. 18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002; 4: 267-73.
86. 18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 2003; 48: 3077-84.
87. 18]Ffluoro-deoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168: 273-80.
88. 31P magnetic resonance studies. J Biol Chem 1991; 266: 3688-94.
89. Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, et al. "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998; 18: 500-9.
90. 3H]methyl]-L-methionine. J Nucl Med 2000; 41: 1250-5.
91. 18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol 1993; 20: 895-9.
92. Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, et al. Re-evaluation of amino acid PET studies: Can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 1993; 34: 1936-43.
93. Lahoutte T, Caveliers V, Camargo SM, Franca R, Ramadan T, Veljkovic E, et al. SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med 2004; 45: 1591-6
94. Ishiwata K, Enomoto K, Sasaki T, Elsinga PH, Senda M, Okazumi S, et al. A feasibility study on L-[1-carbon-11]tyrosine and L-[methyl-carbon-11]methionine to assess liver protein synthesis by PET. J Nucl Med 1996; 37: 279-85.
95. Langen KJ, Jarosch M, Muhlensiepen H, Hamacher K, Broer S, Jansen P, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 2003; 30: 501-8.
96. 18F]fluorotyrosine, a new PET tracer of protein synthesis. J Nucl Med 1989; 30: 1367-72.
97. 11C]alphaaminoisobutyric acid (AIB), a potential radiotracer for imaging and amino acid transport studies in normal and malignant tissues. Int J Nucl Med Biol 1984; 11: 209-14.
98. Bading JR, Kan-Mitchell J, Conti PS. System A amino acid transport in cultured human tumor cells: Implications for tumor imaging with PET. Nucl Med Biol 1996; 23: 779-86.
99. 14Cacetyl)-aminoisobutyric acid. Nucl Med Biol 1996; 23: 359-63.
100. 18F]fluoromethyl-L-tyrosine as tumor imaging tracers by PET. Nucl Med Biol 2004; 31: 191-8.
101. Inoue T, Oriuchi N, Tomiyoshi K, Endo K. A shifting landscape: What will be next FDG in PET oncology? Ann Nucl Med 2002; 16: 1-9.
102. Inoue T, Tomiyoshi K, Higuichi T, Ahmed K, Sarwar M, Aoyagi K, et al. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: A potential tumor-detecting agent. J Nucl Med 1998; 39: 663-7.
103. 123I] iodo-alpha-methyl tyrosine: Comparison with PET, 124IMT and first clinical results. J Nucl Med 1990; 31: 281-6.
104. 125I]iodo-L-tyrosine into U266 human myeloma cells: evidence for system T transport. Nucl Med Biol 2001; 28: 129-34.
105. 131I]iodo-alpha-methyl-L-tyrosine in human monocyte-macrophages. Nucl Med Biol 2004; 31: 365-72.
106. 18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999; 40: 1367-73.
107. 18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999; 40: 205-12.
108. 18F]fluoropropyl)-L-tyrosine as an oncologic PET tracer. Nucl Med Biol 2003; 30: 733-9.
109. 123/125I-2-iodo-L- phenylalanine in an R1M rhabdomyosarcoma athymic mouse model as a potential tumor tracer for SPECT. J Nucl Med 2005; 46: 532-9.
110. 123I]iodo-L-phenylalanine for detection of pancreatic cancer: Basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 532-41.
111. 18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med 1999; 40: 331-8.
112. 18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med 2007; 48: 46-55.
113. Ishiwata K, Kasahara C, Hatano K, Ishii S, Senda M. Carbon-11 labeled ethionine and propionine as tumor detecting agents. Ann Nucl Med 1997; 11: 115-22.
114. 18F)fluorotyrosine. J Nucl Med 1991; 32: 1338-46.
115. 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008; 29: 1176-82
116. 11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003; 30: 868-73.
117. Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R, et al. Methionine uptake by tumor tissue: A microautoradiographic comparison with FDG. J Nucl Med 1995; 36: 484-92.
118. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: A comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med 1997; 38: 280-7.
119. 125I-HSA. Eur J Nucl Med 1999; 26: 333-41.
120. 18F]fluoro-ethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging 2006; 33: 932-9.
121. 18F]Fluoroethyl)-L-tyrosine (FET): A tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging 2002; 29: 1039-46.
122. 18F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging 2002; 29: 648-54.
123. Chang CH, Wang HE, Wu SY, Fan KH, Tsai TH, Lee TW, et al. Comparative evaluation of FET and FDG for differentiating lung carcinoma from inflammation in mice. Anticancer Res 2006; 26: 917-25.
124. 18F-FET uptake. Contrast Media Mol Imaging 2006; 1: 212-20.
125. 18F]fluoromethyl-Ltyrosine for differentiation between tumor and inflammatory tissues. Ann Nucl Med 2005; 19: 589-95.
126. 11C-methionine. J Nucl Med 2006; 47: 679-88.
127. 18F]fluoro-2deoxy-D-glucose in human pancreatic carcinoma xenografts and in inflammation models. Nucl Med Biol 2005; 32: 137-45
128. 11C]-carboxylic acid, a potential tumor-seeking agent. J Nucl Med 1979; 20: 1055-61.
129. 18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: First clinical results. J Nucl Med 2005; 46: 411-6
130. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, et al. Differential diagnosis of lung tumor with positron emission tomography: A prospective study. J Nucl Med 1990; 31: 1927-32.
131. Nettelbladt OS, Sundin AE, Valind SO, Gustafsson GR, Lamberg K, Langstrom B, et al. Combined fluorine-18-FDG and carbon-11methionine PET for diagnosis of tumors in lung and mediastinum. J Nucl Med 1998; 39: 640-7.
132. Inoue T, Kim EE, Wong FC, Yang DJ, Bassa P, Wong WH, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11methionine PET in detection of malignant tumors. J Nucl Med 1996; 37: 1472-6.
133. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: Is a differential diagnosis possible? J Neurosurg 2003; 98: 1056-64.
134. Dethy S, Manto M, Kentos A, Konopnicki D, Pirotte B, Goldman S, et al. PET findings in a brain abscess associated with a silent atrial septal defect. Clin Neurol Neurosurg 1995; 97: 349-53.
135. Tsuyuguchi N, Sunada I, Ohata K, Takami T, Nishio A, Hara M, et al. Evaluation of treatment effects in brain abscess with positron emission tomography: Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine. Ann Nucl Med 2003; 17: 47-51.
136. 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 2006; 47: 776-82.
137. Dethy S, Goldman S, Blecic S, Luxen A, Levivier M, Hildebrand J. Carbon-11-methionine and fluorine-18-FDG PET study in brain hematoma. J Nucl Med 1994; 35: 1162-6.
138. Ogawa T, Hatazawa J, Inugami A, Murakami M, Fujita H, Shimosegawa E, et al. Carbon-11-methionine PET evaluation of intracerebral hematoma: Distinguishing neoplastic from nonneoplastic hematoma. J Nucl Med 1995; 36: 2175-9.
139. O'Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997; 38: 1575-83.
140. 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med 2000; 41: 283-90.
141. Yamada Y, Uchida Y, Tatsumi K, Yamaguchi T, Kimura H, Kitahara H, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998; 39: 1160-6.
142. Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, et al. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 1996; 23: 1345-53.
143. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998; 50: 1316-22.
144. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988; 263: 8350-8.
145. Arner ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995; 67: 155-86.
146. Bading JR, Shields AF. Imaging of cell proliferation: Status and prospects. J Nucl Med 2008; 49(Suppl 2): 64S-80S.
147. 11C)thymidine. Proc Natl Acad Sci U S A 1972; 69: 988-92.
148. Shields AF, Larson SM, Grunbaum Z, Graham MM. Short-term thymidine uptake in normal and neoplastic tissues: Studies for PET. J Nucl Med 1984; 25: 759-64.
149. Shields AF, Lim K, Grierson J, Link J, Krohn KA. Utilization of labeled thymidine in DNA synthesis: Studies for PET. J Nucl Med 1990; 31: 337-42.
150. 11C]thymidine for measurement of cell proliferation in fast dividing tissues. Nucl Med Biol 1993; 20: 359-62.
151. 11C]thymidine. Gastroenterology 1991; 101: 794-9.
152. 11C]thymidine for quantification of cellular proliferation with PET. Int J Rad Appl Instrum [A] 1991; 42: 103-4.
153. Shields AF, Graham MM, Kozawa SM, Kozell LB, Link JM, Swenson ER, et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med 1992; 33: 581-4.
154. Vander Borght TM, Lambotte LE, Pauwels SA, Dive CC. Uptake of thymidine labeled on carbon 2: A potential index of liver regeneration by positron emission tomography. Hepatology 1990; 12: 113-8.
155. Vander Borght T, Pauwels S, Lambotte L, Labar D, De MS, Stroobandt G, et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 1994; 35: 974-82.
156. Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, et al. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res 1999; 59: 615-21.
157. 3H]thymidine, and gallium-67. J Nucl Med 1991; 32: 2118-23.
158. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003; 44: 2027-32.
159. 125I]iodo-2′- deoxyuridine in rat brain tumors: Diagnostic and therapeutic implications in humans. Cancer Res 1990; 50: 5199-203.
160. Kriss JP, Maruyama Y, Tung LA, Bond SB, Revesz L. The fate of 5-bromodeoxyuridine, 5-bromodeoxycytidine, and 5-iododeoxycytidine in man. Cancer Res 1963; 23: 260-8.
161. 18F-5-fluorouridine in rats. Eur J Nucl Med 1984; 9: 185-9
162. Bergstrom M, Lu L, Fasth KJ, Wu F, Bergstrom-Pettermann E, Tolmachev V, et al. In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. J Nucl Med 1998; 39: 1273-9.
163. 76Br-BrdU in DNA of brain tumors after a PET study does not support its use as a proliferation marker. Nucl Med Biol 2001; 28: 59-65.
164. Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med 1994; 35: 1407-17.
165. Tjuvajev J, Muraki A, Ginos J, Berk J, Koutcher J, Ballon D, et al. Iododeoxyuridine uptake and retention as a measure of tumor growth. J Nucl Med 1993; 34: 1152-62.
166. 18F-5-fluorodeoxyuridine in animals. Eur J Nucl Med 1983; 8: 258-61.
167. Washtien WL, Santi DV. Assay of intracellular free and macromolecular-bound metabolites of 5-fluorodeoxyuridine and 5-fluorouracil. Cancer Res 1979; 39: 3397-3404.
168. 76Br-BFU as proliferation markers. J Nucl Med 2002; 43: 1688-98.
169. 76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats. J Nucl Med 2000; 41: 1746-52.
170. 76Br]bromo-2′-fluoro-2pm-deoxyuridine as a ligand for tumour proliferation: Validation in an animal tumour model. Eur J Nucl Med Mol Imaging 2002; 29: 19-27.
171. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol 1996; 23: 17-22.
172. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4: 1334-6
173. Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 2006; 66: 8558-64.
174. Paproski RJ, Ng AM, Yao SY, Graham K, Young JD, Cass CE. The Role of Human Nucleoside Transporters in Uptake of 3′-Deoxy-3′-Fluorothymidine. Mol Pharmacol 2008 [in press]
175. 18F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002; 29: 1174-81.
176. 18F-FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 2004; 31: 169-78.
177. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: Validation studies in patients with lung cancer. J Nucl Med 2005; 46: 274-82.
178. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002; 43: 1210-7.
179. 18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res 2003; 63: 2681-7.
180. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63: 3791-8.
181. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991; 266: 9032-8.
182. Eriksson S, Kierdaszuk B, Munch-Petersen B, Oberg B, Johansson NG. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 1991; 176: 586-92.
183. 18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: An in vitro study. Br J Cancer 2008; 99: 481-7.
184. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004; 45: 695-700.
185. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30: 988-94.
186. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003; 52(11): 1602-1606.
187. 18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: Comparison with 2-deoxy-2-18f-fluoro-D-glucose. J Comput Assist Tomogr 2008; 32: 432-7.
188. 18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62: 3331-4.
189. 18F-FDG: A comparative analysis. J Nucl Med 2007; 48: 1945-50.
190. 188Re radiation in an MCF7 cell line containing dominant-negative mutant p53. Nucl Med Biol 2007; 34: 425-32.
191. 18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;,65: 4202-10.
192. 18F-FDG. J Nucl Med 2005; 46: 945-52.
193. 18F]fluorothy-midine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005; 65: 10104-12.
194. Saga T, Kawashima H, Araki N, Takahashi JA, Nakashima Y, Higashi T, et al. Evaluation of primary brain tumors with FLTPET: Usefulness and limitations. Clin Nucl Med 2006; 31: 774-80.
195. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8: 3315-23.
196. 18F-FDG. J Nucl Med 2003; 44: 1426-31.
197. 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006; 129: 393-401.
198. 18F]FLT uptake after chemotherapy: An experimental study. Eur J Nucl Med Mol Imaging 2002; 29: 1462-9.
199. Kawai H, Toyohara J, Kado H, Nakagawa T, Takamatsu S, Furukawa T, et al. Acquisition of resistance to antitumor alkylating agent ACNU: A possible target of positron emission tomography monitoring. Nucl Med Biol 2006; 33: 29-35.
200. Yau K, Price P, Pillai RG, Aboagye E. Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors. Eur J Nucl Med Mol Imaging 2006; 33: 981-7.
201. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005; 46: 1948-58.
202. Kanaji N, Bandoh S, Takano K, Kadota K, Haba R, Matsunaga T, et al. Positron emission tomography-positive squalene-induced lipoid pneumonia confirmed by gas chromatography-mass spectrometry of bronchoalveolar lavage fluid. Am J Med Sci 2008; 335: 310-4.
203. 18F-fluoro-3′-deoxy-L-thymidine: A new tracer for staging metastatic melanoma? J Nucl Med 2003; 44: 1927-32.
204. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 2007; 48: 726-35.
205. Adams DO. The granulomatous inflammatory response. A review. Am J Pathol 1976; 84: 164-92.
206. Hopper KE. Kinetics of macrophage recruitment and turnover in peritoneal inflammatory exudates induced by Salmonella or thioglycollate broth. J Leukoc Biol 1986; 39: 435-46.
207. Jutila MA, Banks KL. Locally dividing macrophages in normal and inflamed mammary glands. Clin Exp Immunol 1986; 66: 615-24.
208. Jutila MA, Banks KL. Increased macrophage division in the synovial fluid of goats infected with caprine arthritis-encephalitis virus. J Infect Dis 1988; 157: 1193-1202.
209. Diniz C, Borges F, Santana L, Uriarte E, Oliveira JM, Goncalves J, et al. Ligands and therapeutic perspectives of adenosine A(2A) receptors. Curr Pharm Des 2008; 14(17): 1698-722.
210. Hamoudeh M, Kamleh MA, Diab R, Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008; 60(12): 1329-46.
211. Wagner CC, Muller M, Lappin G, Langer O. Positron emission tomography for use in microdosing studies. Curr Opin Drug Discov Devel 2008; 11(1): 104-10.